Table 2 Univariate and multivariate analyses of clinical parameters for the prediction of overall and progression-free survival
From: Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma
Clinical parameters | Overall survival | Progression-free survival | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
HR | P | Adjusted HR (95 % CI) | P | HR | P | Adjusted HR (95 % CI) | P | |
Age (year) | ||||||||
≦50 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
>50 | 1.09 | 0.540 | 1.08 (0.82–1.41) | 0.598 | 1.10 | 0.436 | 1.08 (0.84–1.39) | 0.543 |
Sex | ||||||||
Male | 1.00 | 1.00 | 1.00 | 1.00 | ||||
Female | 0.93 | 0.634 | 1.06 (0.78–1.44) | 0.695 | 0.97 | 0.844 | 1.02 (0.77–1.35) | 0.889 |
Tumor location | ||||||||
Tibia/femur | 1.00 | 1.00 | ||||||
Elsewhere | 0.99 | 0.963 | 0.89 | 0.378 | ||||
Pathological fracture | ||||||||
Yes | 1.00 | 1.00 | ||||||
No | 0.81 | 0.275 | 0.98 | 0.887 | ||||
Tumor size | 1.00 | |||||||
<8 cm | 1.00 | 1.04 | 0.754 | |||||
≥8 cm | 1.09 | 0.524 | ||||||
ALP | ||||||||
Normal | 1.00 | 1.00 | ||||||
Elevated | 1.28 | 0.094 | 1.30 | 0.055 | ||||
Clinical stagea | ||||||||
I–II | 1.00 | 1.00 | 1.00 | 1.00 | ||||
III | 4.63 | 0.000 | 2.49 (1.66–3.72) | 0.000 | 3.32 | 0.000 | 2.24 (1.59–3.15) | 0.000 |
Metastasis at diagnosis | ||||||||
Absent | 1.00 | 1.00 | 1.00 | 1.00 | ||||
Present | 5.09 | 0.000 | 2.43 (1.69–3.49) | 0.000 | 3.42 | 0.000 | 1.72 (1.23–2.40) | 0.002 |
Post-chemotherapy | ||||||||
Yes | 1.00 | 1.00 | ||||||
No | 1.02 | 0.865 | 1.05 | 0.687 | ||||
NLR | ||||||||
Low NLR | 1.00 | 1.00 | 1.00 | 1.00 | ||||
High NLR | 2.65 | 0.000 | 1.80 (1.35–2.41) | 0.000 | 2.24 | 0.000 | 1.65 (1.26–2.15) | 0.000 |
PLR | ||||||||
Low PLR | 1.00 | 1.00 | 1.00 | 1.00 | ||||
High PLR | 1.84 | 0.000 | 1.27 (0.93–1.73) | 0.136 | 1.57 | 0.001 | 1.17 (0.88–1.55) | 0.273 |